April 2025
01_natural_expansion_in_tm | 01_april_fools | 02_unknown_problem_obviousness | 03_PTE_reissue_drug_patents | 04_provisional_rights | 22_ai/ml_eligibility | 23_ai/ml_eligibility_part2 | 24_related_app_statement | 25_aapa_ipr_statute | 28_aapa_institution_dec
March 2025
03_tip_inequitable_conduct | 04_delete_priority_cip | 05_tm_intent_to_use | 06_product_by_process | 07_mRNA_litigation | 10_limitations_into_claims | 11_fix_abuse_and_eligibility | 12_claim_scope_rulings | 13_if_then_else_claims | 14_ai_replacing_lawyers | 17_Saudi_universities_tops_in_patents | 18_separate_claim_elements | 19_mark_interpretation | 20_copyright_authorship | 21_args_not_made_in_pet | 24_board_dis_reqs | 25_collateral_estoppel | 26_bus_method_eligibility | 27_monetization | 28_prosecution_disclaimer | 31_provisional_priority
February 2025
06_ipr_invalidity_rate | 07_design_patents | 10_Turdle™ | 11_AI_software | 12_SAFE | 13_AI_copyright_infringement | 17_DOGE_USPTO | 18_eligibility_fix | 19_solar_mount | 20_legal_fiction_eligibility | 21_derivation_proceeding | 24_reissue_app | 25_blackberry_case | 26_AI_computer_itself | 27_supplemental_exam | 28_Levin_College_Of_law